Dr. Jordan Emont, an OB/GYN certified by the Menopause Society and founder of Meridian Medical, told members that millions of breast cancer survivors are refused hormone therapy based on older trials that used synthetic progestins, not the transdermal estradiol and micronized progesterone used now.
The evidence she walked through: the Stockholm trial, with 10-year follow-up, found no increase in recurrence in ER-positive patients on tamoxifen plus HRT. HABITS, stopped early and methodologically weaker, did find one. Neither tested modern regimens.
Her bottom line was that survivors face greater long-term mortality from cardiovascular disease and osteoporosis than from recurrence, yet are routinely denied HRT. She argued for individualized risk stratification using receptor status, tumor genetics (ctDNA, Oncotype, Breast Cancer Index) and patient preference, rather than a blanket contraindication.
Key takeaways
- Breast cancer is not one disease. ER-negative survivors have front-loaded recurrence in the first five years, then less than 1% per year.
- Duavee (conjugated estrogens plus bazedoxifene) acts as a SERM in breast tissue and is underused in ER-positive patients who need symptom relief.
- Preclinical data suggest testosterone may be protective in ER-positive tumors.
- Neurokinin antagonists treat vasomotor and sleep symptoms without systemic hormone exposure in the first five years.
- Even 4 mcg vaginal estradiol can cause breast sensitivity in some survivors. Dose matters.
- GLP-1 agonists and metformin add anti-growth signaling through insulin sensitization in survivors with metabolic risk.
From Buzz in the chat, the longevitydocs™ Sunday newsletter, May 26, 2026. Member discussion, not clinical guidance.
Originally published in The Longevity Medicine Intelligence newsletter.
